Altimmune Past Earnings Performance
Past criteria checks 0/6
Altimmune's earnings have been declining at an average annual rate of -21.9%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been declining at an average rate of 45.1% per year.
Key information
-21.9%
Earnings growth rate
22.4%
EPS growth rate
Biotechs Industry Growth | 11.5% |
Revenue growth rate | -45.1% |
Return on equity | -53.6% |
Net Margin | -22,626.1% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Altimmune makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 0 | -93 | 19 | 0 |
31 Dec 23 | 0 | -88 | 18 | 0 |
30 Sep 23 | 0 | -78 | 18 | 0 |
30 Jun 23 | 0 | -81 | 18 | 0 |
31 Mar 23 | 0 | -85 | 17 | 0 |
31 Dec 22 | 0 | -85 | 17 | 0 |
30 Sep 22 | 3 | -87 | 17 | 0 |
30 Jun 22 | 3 | -97 | 17 | 0 |
31 Mar 22 | 4 | -102 | 16 | 0 |
31 Dec 21 | 4 | -97 | 15 | 0 |
30 Sep 21 | 3 | -84 | 16 | 0 |
30 Jun 21 | 6 | -68 | 16 | 0 |
31 Mar 21 | 7 | -60 | 15 | 0 |
31 Dec 20 | 8 | -49 | 13 | 0 |
30 Sep 20 | 6 | -43 | 11 | 0 |
30 Jun 20 | 4 | -36 | 9 | 0 |
31 Mar 20 | 5 | -22 | 9 | 0 |
31 Dec 19 | 6 | -21 | 9 | 0 |
30 Sep 19 | 8 | -42 | 9 | 0 |
30 Jun 19 | 10 | -34 | 9 | 0 |
31 Mar 19 | 11 | -40 | 9 | 0 |
31 Dec 18 | 10 | -42 | 10 | 0 |
30 Sep 18 | 11 | -29 | 9 | 0 |
30 Jun 18 | 13 | -58 | 10 | 0 |
31 Mar 18 | 13 | -52 | 10 | 0 |
31 Dec 17 | 11 | -51 | 8 | 0 |
30 Sep 17 | 9 | -43 | 8 | 0 |
30 Jun 17 | 5 | -16 | 8 | 0 |
31 Mar 17 | 3 | -14 | 7 | 0 |
31 Dec 16 | 3 | -11 | 6 | 0 |
30 Sep 16 | 3 | -10 | 5 | 0 |
31 Dec 15 | 5 | -7 | 5 | 0 |
31 Dec 14 | 6 | -1 | 1 | 0 |
Quality Earnings: 0A4C is currently unprofitable.
Growing Profit Margin: 0A4C is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0A4C is unprofitable, and losses have increased over the past 5 years at a rate of 21.9% per year.
Accelerating Growth: Unable to compare 0A4C's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0A4C is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.9%).
Return on Equity
High ROE: 0A4C has a negative Return on Equity (-53.64%), as it is currently unprofitable.